News | May 02, 2011

First Patients Enrolled in Study of Self-Apposing Coronary Stent

May 2, 2011 – The mid-point for enrollment was reached in of the international APPOSITION III study of Stentys self-apposing coronary stent. About 250 patients are now enrolled out of a total of 500. The trial primary endpoint is major adverse cardiac events (MACE) at 12 months post-procedure.
 
“All cardiologists are extremely excited to be part of the APPOSITION III study and to routinely use the Stentys Self-Apposing Stent in treating AMI patients,” said study investigator Robert Jan van Geuns, M.D., Ph.D., Thorax Center at Erasmus Medical Center, Rotterdam, the Netherlands.
 
The stent is self-apposing to fit snugly into the contour of a blood vessel. Its shape and diameter adapt to the anatomic changes of the coronary arteries during the post-acute myocardial infarction (AMI) phase. The APPOSITION II randomized trial compared the Self-Apposing Stent with a conventional, market-leading stent in patients suffering a heart attack. It showed that, three days after an AMI, 28 percent of patients treated with conventional stents displayed significant malapposition, meaning that the stent was not completely in contact with the artery wall. Malapposition puts AMI patients at significant risk of potential fatal complications such as a blockage of the stent (in-stent thrombosis). In contrast, none of the patients treated with the Stentys stent had stent malapposition.
 
For more information: www.stentys.com

Related Content

Studycast PACS Adds Two-factor Authentication to Improve Data Privacy and Security
News | Cybersecurity | June 12, 2019
Core Sound Imaging announced the addition of two-factor authentication (2FA) to the security measures available for the...
Aidoc Earns FDA Approval for AI for C-spine Fractures
Technology | Artificial Intelligence | June 11, 2019
Radiology artificial intelligence (AI) provider Aidoc announced the U.S. Food and Drug Administration (FDA) has cleared...
PaxeraHealth Wins Four New PACS Projects in Chile
News | PACS | June 07, 2019
Picture archiving and communication system/radiology information system (PACS/RIS) developer PaxeraHealth has won four...
AI Biomarker Demonstrates High Predictive Power for Lung Cancer Immunotherapy
News | Artificial Intelligence | May 31, 2019
Lunit announced an abstract presentation of its artificial intelligence (AI) precision medicine research portfolio at...
Dynamic Digital Radiography Used to Assess Undifferentiated Dyspnea
News | Digital Radiography (DR) | May 29, 2019
A clinical study presented at the American Thoracic Society (ATS) 2019 annual meeting, May 17-22 in Dallas, described...
Leica Biosystems Receives FDA Clearance for Aperio AT2 DX Digital Pathology System
Technology | Digital Pathology | May 29, 2019
Leica Biosystems has received clearance from the U.S. Food and Drug Administration (FDA) to market its Aperio AT2 DX...
New Blood Test Detects Colorectal Cancer Recurrence Up to 16.5 Months Earlier
News | Oncology Diagnostics | May 28, 2019
A new clinical study shows that Natera's Signatera test identified colorectal cancer recurrence up to 16.5 months...
Intelerad Showcases Clario SmartWorklist at SIIM 2019
News | PACS Accessories | May 28, 2019
The Clario SmartWorklist intelligently manages picture archiving and communication system (PACS) reading workflow by...
Proton Therapy Lowers Risk of Side Effects Compared to Conventional Radiation
News | Proton Therapy | May 23, 2019
Cancer patients getting proton therapy instead of traditional photon radiation are at a significantly lower risk of...